Journals in Microbiology and virology

1-10 of 102 results in All results

Acta Tropica

ISSN: 0001-706X
5 Year impact factor: 2.7
Impact factor: 2.7

Acta Tropica, is an international journal on infectious diseases that covers public health sciences and biomedical research with particular emphasis on topics relevant to human and animal health in the tropics and the subtropics. Its scope includes the biology of pathogens and vectors, host-parasite relationships, mechanisms of pathogenicity, clinical disease and treatment, and we welcome contributions in basic or applied research in disciplines such as epidemiology, disease ecology, diagnostics, interventions and control, mathematical modeling, public health and social sciences, climate change, parasite and vector taxonomy, host and parasite genomics, biochemistry and immunology and vaccine testing. Contributions may be in the form of original research papers, review articles, short communications, opinion articles, or letters to the Editors. Only manuscripts of high scientific significance and innovation will be considered for publication. Manuscripts of minimal international relevance, case reports, and control strategies at very early inconclusive laboratory stages of development will not be considered for publication. Important Guidelines for Acceptance Editors and the Editorial Board of Acta Tropica provide the following guidelines to help authors prepare manuscripts of high quality that can be considered for publication. Maximize your chances of acceptance by making sure your manuscript: Matches the scientific scope of the journal, Presents results that significantly advance science including innovative new approaches, Meets quality standards of presentation and literature citation, Demonstrates potential health or biomedical impact. The above points are critical for publication of original papers. Be aware Editors carefully evaluate initial manuscript submissions and only those meeting the above criteria will be forwarded to review. If reviewed favorably and the authors seriously address all concerns, than chances of acceptance are increased. Review papers, in addition, are expected to carefully synthesize the literarture and make recommendations to advance respective scientific fields. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Alexandria Journal of Medicine

ISSN: 2090-5068

As of 1 January 2019 the journal has been transferred to the new Publisher, Taylor and Francis.The Alexandria Journal of Medicine is concerned with providing a venue for publication of research, with a particular focus on diseases of high prevalence in MENA (Middle East and North Africa) and its comparison to their profile worldwide. Manuscripts from the international scientific community are also welcome to cater to the interests of our broad readership, both regional and worldwide and to increase the opportunities for fruitful interregional scientific collaboration. The journal publishes original research articles, review articles, short communications and clinical trials in an open access format. Furthermore, time to first decision has been set to be within 6 weeks to facilitate rapid dissemination of high quality accepted articles.

Algal Research

ISSN: 2211-9264
5 Year impact factor: 5.5
Impact factor: 5.1

Algal Research is an international phycology journal covering all areas of emerging technologies in algae biology, biomass production, cultivation, harvesting, extraction, bioproducts, biorefinery, engineering, and econometrics. Algae is defined to include cyanobacteria, microalgae, macroalgae, and protists and symbionts of interest in biotechnology. The journal publishes original research and reviews for the following scope: algal biology, including but not exclusive to: phylogeny, biodiversity, molecular traits, metabolic regulation, and genetic engineering, algal cultivation, e.g. phototrophic systems, heterotrophic systems, and mixotrophic systems, algal harvesting and extraction systems, biotechnology to convert algal biomass and components into biofuels and bioproducts, e.g., nutraceuticals, pharmaceuticals, animal feed, plastics, etc. algal products and their economic assessment Papers in the latter topics should include characterization and analysis in support of such processes and technologies, for example:approaches to biorefinery and biomass characterization, sustainability assessments and analyses, such as techno-economic, life cycle, and resource assessments of systems and processes using algae as a main source of biomass. The journal will not consider manuscripts where the core concept is the experimental design (RSM, CCD or other) in the opitmization of a process, or the biological activity of algae extracts without full characterization and identification of the compounds responsible for the bioactivity. Review articles, book reviews and commentaries should only be submitted after consultation with the Editors. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Review articles, book reviews and commentaries should only be submitted after consultation with the Editors. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

American Journal of Infection Control

ISSN: 0196-6553
5 Year impact factor: 3.4
Impact factor: 4.9

AJIC covers key topics and issues in infection control and epidemiology. Infection control professionals, including physicians, nurses, and epidemiologists, rely on AJIC for peer-reviewed articles covering clinical topics as well as original research. As the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC). AJIC is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention. AJIC also publishes infection control guidelines from APIC and the CDC. AJIC is included in Index Medicus and CINAHL. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Image - American Journal of Infection Control

Anaerobe

ISSN: 1075-9964
5 Year impact factor: 2.9
Impact factor: 2.3

Anaerobe is essential reading for those who wish to remain at the forefront of discoveries relating to life processes of strictly anaerobes. The journal is multi-disciplinary, and provides a unique forum for those investigating strictly anaerobic organisms that cause infections in humans and animals, as well as anaerobes that play roles in microbiomes or environmental processes. As well as anaerobic or microaerophilic bacteria, Anaerobe will also consider manuscripts on anaerobic archaea, fungi, protists and bacteriophages of anaerobes. Relevant topics fall into the broad categories of: Anaerobes in human and animal diseases Anaerobes in the microbiome Anaerobes in the environment Anaerobes in industrial processes (including biofuels and waste management) Microbial ecology of anaerobes Clinical microbiology involving anaerobes Pathogenesis of anaerobic organisms (including their toxins) Molecular biology and genetics of anaerobes Taxonomy of anaerobes Physiology of anaerobes Papers describing innovative methodologies, technologies and applications to investigate anaerobic microorganisms are also of interest. Manuscripts describing novel species of obligate anaerobes will be reviewed, if the description of the new species also includes information showing novel phenotypic characteristics, pathogenicity and/or unique metabolic activity within the microbiome from which it was isolated. Manuscripts describing novel anaerobic species that are only different from other related members of a genus based on genotype will not be reviewed. Manuscript types accepted (see Guide for Authors for more information): Original research articles Original research reports on one or more of the above listed categories. Up to 4000 words, not including a structured abstract, figures, tables and references. Short Communications Presentation of brief observations that do not warrant a full-length publication. Up to 1500 words not including abstract, figures, tables and references. Short communications should report complete datasets and not preliminary findings. Reviews and minireviews Reviews are typically 7,000 words in length including relevant tables and/or figures. Mini-reviews are typically restricted to 2,500 words in length. *New from March 1st 2023: Anaerobe no longer accepts unsolicited reviews and standalone mini-reviews. Proposals for reviews and mini-reviews within the topics mentioned above are welcome for consideration by the journal. Please provide a proposed title and detailed outline of the topic to be covered to an editor-in-chief by email. Case reports Presentation of a short report on a significant clinical observation, preceded by a minireview (up to 2500 words) of the literature describing the background of similar cases/infections, what is known about the associated microbe, and other clinically relevant information. *New from March 2023: Case Reports will only be considered in this new format. Commentaries Occasionally, Anaerobe will consider publication of commentaries on important new work in the field. Such commentaries will be invited by the editors-in-chief. Suggestions for commentaries may be emailed to an Editor-in-Chief. Unsolicited commentaries will not be considered. Please note: 1. Anaerobe does not accept manuscripts on descriptive, sequence-based surveys of microbiomes, even if the environments of the sampled ecosystems select for anaerobic species. However, when studies such as these are accompanied by direct, mechanistic assays of strictly anaerobic components, they will be considered for publication. 2. Anaerobe will not consider manuscripts that deal only with descriptive accounts of the beneficial effects of potentially novel probiotic strains, unless such strains belong to strictly anaerobic species that have previously not been associated with probiotic features. Anaerobe will continue to consider manuscripts for publication that address determinations of the specific mechanism(s) of action of anaerobic probiotic strains.

Antiviral Research

ISSN: 0166-3542
5 Year impact factor: 5.8
Impact factor: 7.6

Antiviral Research publishes research reports, short communications, review articles and commentaries on the control of viral infections in humans and animals. Its scope encompasses: antiviral drugs, antibodies and host-response modifiers, including their synthesis, in vitro and in vivo testing and mechanisms of action. new or improved vaccines against viral infections of humans; assessments of drug and vaccine safety; evolution of drug- or vaccine-resistant viruses and the development of effective countermeasures; identification and validation of new drug targets; laboratory animal models of viral diseases; pathogenesis of viral diseases and mechanisms of viral evasion of host immune responses. We encourage the submission of manuscripts describing the activity of well-defined chemical compounds for the treatment of viral diseases of humans and vertebrate animals. We also publish manuscripts on the protective activity of vaccines for humans, and we will consider reports of the testing of veterinary vaccines in the target animal species. All papers must include a sufficiently detailed description of methods to permit other investigators to replicate the experiments. Authors reporting the antiviral effect of a novel small-molecule drug must reveal its chemical structure. Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis. Note: Antiviral Research may choose not to publish certain COVID-19 papers. The COVID-19 pandemic has focused attention on the possibility that patients infected with SARS-CoV-2 might benefit from treatment with certain licensed drugs approved for conditions other than viral infection. Reports that various medications inhibit the replication of the virus in vitro have been widely publicized in news articles and on medical websites, giving the impression that compounds still in the earliest stage of evaluation may be used to prevent or treat COVID-19. Such misunderstanding may result in the inappropriate use of a drug by physicians and to self-treatment by people who obtain it from other sources, with a risk of toxicity. This may be a particular problem when a medication is available without prescription as a veterinary product. Hoarding or inappropriate use of a drug intended to treat another disease may also make it unavailable to patients with that disease. The editors of Antiviral Research may therefore choose not to publish certain COVID-19 manuscripts, when in our judgment publication is likely to result in harm, without clear evidence of benefit. The scope of AVR also includes the prevention and treatment of viral diseases of vertebrate animals. We do not publish reports on viral diseases of plants or of insects, crustaceans or other invertebrates. Studies of viral diseases of livestock and companion animals must be clearly related to the development of realistic therapies. Papers on veterinary vaccines should report findings in the target animal species. We discourage the submission of manuscripts reporting the antiviral activity of unpurified natural products, or of partially purified substances of natural origin for which a mechanism of action has not been determined. Manuscripts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will not be considered for publication. Articles describing antiseptics with broad-spectrum antimicrobial activity will not be accepted. We also discourage submission of in silico docking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays. Citations of reports that have not undergone peer review must include the note "[not peer-reviewed]." Antiviral Research is an official publication of the International Society for Antiviral Research (http://www.isar-icar.com). Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Atherosclerosis Plus

ISSN: 2667-0895
5 Year impact factor: 1.6
Impact factor: 1.6

Atherosclerosis Plus is supported by the European Atherosclerosis Society.Atherosclerosis Plus publishes both original research and review papers that address the key aspects of atherosclerosis, including its pathogenesis and genetic basis, its risk factors (e.g. dyslipidemia and lipid related disorders, hypertension, obesity, diabetes), and the impact of lifestyle modifications (e.g., smoking, diet, physical activity) and nutritional and pharmacological interventions aimed at the primary and secondary prevention of cardiovascular diseases and related conditions. Types of papers that can be submitted for consideration by the Editorial Board include Original Research Papers, Brief Communications, Case Reports, and Review Articles. Finally, the journal periodically publishes special theme issues devoted to areas of current interest.

Biochimica et Biophysica Acta: Gene Regulatory Mechanisms

ISSN: 1874-9399
5 Year impact factor: 4.3
Impact factor: 4.7

BBA Gene Regulatory Mechanisms includes reports that describe novel insights into mechanisms of transcriptional, post-transcriptional and translational gene regulation. Special emphasis is placed on papers that identify epigenetic mechanisms of gene regulation, including chromatin, modification, and remodeling. This section also encompasses mechanistic studies of regulatory proteins and protein complexes; regulatory or mechanistic aspects of RNA processing; regulation of expression by small RNAs; genomic analysis of gene expression patterns; and modeling of gene regulatory pathways. Papers describing gene promoters, enhancers, silencers or other regulatory DNA regions must incorporate significant functions studies. The journal does not favorably review manuscripts identifying a miRNA-target pair without additional insights into the repression mechanism or significant advances in understanding regulatory pathways. In addition, the following elements should be an integral part of the study: •In silico prediction of miRNA targets must be experimentally verified using appropriate luciferase constructs and assays; •To exclude non-functional miRNA/mRNA interactions a reporter system including the whole 3'UTR of the target gene downstream the "luciferase" or GFP should be considered; •Any miRNA modulation should be validated by measuring the expression of the putative protein Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Image - Biochimica et Biophysica Acta: Gene Regulatory Mechanisms

Biofilm

ISSN: 2590-2075
5 Year impact factor: 6.8
Impact factor: 6.8

Biofilm is a multidisciplinary, gold open access journal focused on hypothesis- or discovery-driven studies on microbial biofilms (i.e. multicellular communities, including surface-attached biofilms and suspended aggregates). The journal will cover biofilms in all (micro)environments, including clinical and industrial settings and the natural environment. We accept articles that describe the basic biology of single or mixed-species biofilms (irrespective of the organism), manuscripts dealing with applied/translational aspects of biofilms, as well as manuscripts describing innovative biofilm methods. Biofilm aims to bring together different disciplines to significantly advance the knowledge of microbial communities, and encourages exploring the interfaces between these disciplines.

Biologicals

ISSN: 1045-1056
5 Year impact factor: 1.6
Impact factor: 1.7

Biologicals provides a modern and multidisciplinary international forum for news, debate, and original research on all aspects of biologicals used in human and veterinary medicine. The journal publishes original papers, reviews, and letters relevant to the development, production, quality control, and standardization of biological derived from both novel and established biotechnologies. Special issues are produced to reflect topics of particular international interest and concern.Three types of papers are welcome: original research reports, short papers, and review articles. The journal will also publish comments and letters to the editor, book reviews, meeting reports and information on regulatory issues. Research Areas Include Areas relevant to biologicals for human and veterinary use such as: • Bacterial vaccines • Blood products • Cell biology • Cell culture technology • Cellular immunology • Cytokines and allied mediators • Diagnostics • Downstream processing • Gene transfer and expression • General bacterology • General virology, endogenous and adventitious viruses • Hormones • Immunochemistry • Molecular biology • Monoclonal antibodies • Parasitology • Prion and prion disease • Protein chemistry • Toxins • Toxoids • Viral vaccines